Cardiovascular Diseases

The department is focusing on Cardiovascular Diseases, addressing conditions such as Acute Coronary Syndrome and Atrial Fibrillation. Current studies evaluate the novel anticoagulant Milvexian for stroke prevention and the potential of Abelacimab in patients unsuitable for standard oral anticoagulants, aiming to reduce the risk of stroke and overall MACE.

  • Anticoagulant therapy optimization
  • Prevention of cardioembolic events
  • Reduction of major adverse cardiac events
  • Safety assessment of new oral agents

Multiprofile Hospital For Active Treatment Dr. Tota Venkova AD in Gabrovo is contributing valuable data on cardiovascular risk management through its nine active trials.

Neoplasms

Research in the Neoplasms area centers on Advanced Breast Cancer, specifically estrogen‑receptor positive, HER2‑negative disease. The trial comparing ARV‑471 with fulvestrant seeks to extend progression‑free survival and explore benefits for patients with ESR1 mutations.

  • Targeted hormone therapy development
  • Comparative efficacy of novel agents
  • Biomarker‑driven treatment strategies
  • Improving progression‑free survival outcomes

The hospital’s oncology team collaborates with international partners to bring innovative breast‑cancer options to the region.

Nutritional and Metabolic Diseases

In the field of Nutritional and Metabolic Diseases, investigators are studying patients with Severe Hypertriglyceridemia. The subcutaneous agent Olezarsen is being evaluated for its ability to lower triglyceride levels and mitigate associated cardiovascular risk.

  • Lipid‑lowering therapeutic strategies
  • Subcutaneous delivery assessment
  • Metabolic risk reduction
  • Safety profiling of novel agents

By addressing high‑risk lipid disorders, the site supports broader efforts to improve metabolic health in the community.

Respiratory Tract Diseases

The Respiratory Tract Diseases program includes trials for both Asthma and Chronic Obstructive Pulmonary Disease (COPD). Studies evaluate the biologic Astegolimab and the inhaled agents CHF6001 and Tanimilast as add‑on therapies to standard inhaled corticosteroid/long‑acting β2‑agonist regimens, targeting a reduction in exacerbation rates.

  • Exacerbation rate reduction
  • Add‑on inhaled therapy evaluation
  • Biologic treatment for COPD
  • Management of uncontrolled asthma

Respiratory specialists at the hospital are advancing care for patients with chronic lung conditions through these innovative trials.

Virus Diseases

Within the Virus Diseases portfolio, the focus is on preventing seasonal influenza. The study of the adjuvanted vaccine Fluad compares its efficacy and immunogenicity to a non‑adjuvanted trivalent vaccine in adults aged 65 and older, aiming to demonstrate non‑inferior protection against influenza A and B strains.

  • Adjuvanted vaccine assessment
  • Efficacy in senior populations
  • Safety of seasonal influenza vaccines
  • Comparative immunogenicity analysis

The hospital’s vaccination trial contributes to public‑health strategies for protecting vulnerable elderly groups against viral respiratory illness.